pISSN 1226-6051
eISSN 2508-786X

Table. 2.

Table. 2.

Usage of immunosuppressants: everolimus with low dose tacrolimus group and conventional dose tacrolimus group

EVR+Low TAC (N=40) TAC (N=78) p-value
Time between cohort entry and transplant date, n (%) 0.693
23-28 days 2 (5.0) 3 (3.8)
29-180 days 12 (30.0) 30 (38.5)
181-365 days 12 (30.0) 23 (29.5)
>366 days 14 (35.0) 20 (25.6)
Induction, n (%) 0.848
Basiliximab 34 (85.0) 66 (84.6)
Rituximab 8 (20.0) 13 (16.7)
Neither 1 (2.5) 1 (1.3)
Concurrent usage of MMF, n (%)
Cohort entry date 28 (70.0) 62 (79.5) 0.251
1 year after cohort entry date 18 (45.0) 44 (56.4) 0.240
Tacrolimus level, ng/mL, mean±SD
Cohort entry date 7.3±3.7 8.0±3.3 0.287
1 year after cohort entry date 3.3±2.1 6.7±3.6 0.000*

EVR+Low TAC: everolimus+low dose tacrolimus cohort

TAC: conventional dose tacrolimus cohort MMF: mycophenolate mofetil

SD: standard deviation

*
p<0.05

Korean J Clin Pharm 2021;31:44-52 https://doi.org/10.24304/kjcp.2021.31.1.44
© 2021 Korean J Clin Pharm